Author:
Price Richard L.,Kaur Balveen,Chiocca E. Antonio
Reference142 articles.
1. Ackermann M, Chou J, Sarmiento M et al (1986) Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of herpes simplex virus genome. J Virol, 58: 843–850
2. Adusumilli PS, Stiles BM, Chan MK et al (2006) Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med, 8: 603–615
3. Advani SJ, Chung SM, Yan SY et al (1999) Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res, 59: 2055–2058
4. Aghi M, Rabkin SD, Martuza RL (2007) Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res, 67: 440–444
5. Aghi M, Visted T, Depinho RA et al (2008) Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene, 27: 4249–4254